BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series

David J. Bartlett, Andrew J. Erie, Francis I. Baffour, Stephen Broski, Katrina N. Glazebrook

Research output: Contribution to journalArticlepeer-review

Abstract

BRAF and MEK inhibitor combination therapy is the standard treatment for patients with BRAF V600E mutant metastatic melanoma. Neutrophilic panniculitis is a known rare complication of BRAF inhibitor therapy and can act as a potential mimic of melanoma metastases on 18F-FDG PET/CT. In this case series, we present three cases of BRAF inhibitor-induced panniculitis in patients being treated for BRAF-mutant metastatic melanoma and emphasize the use of ultrasound to differentiate between panniculitis lesions, which are typically ill-defined echogenic masses and subcutaneous soft tissue melanoma metastases, which present as hypoechoic vascular masses.

Original languageEnglish (US)
JournalSkeletal Radiology
DOIs
StateAccepted/In press - 2020

Keywords

  • BRAF
  • Diagnostic ultrasound
  • Melanoma
  • Panniculitis
  • PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series'. Together they form a unique fingerprint.

Cite this